# Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa

> **NCT01113281** · PHASE1 · COMPLETED · sponsor: **Serum Life Science Europe GmbH** · enrollment: 24 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** VPM1002 live vaccine
- **BIOLOGICAL:** commercially available live vaccine BCG

## Key facts

- **NCT ID:** NCT01113281
- **Lead sponsor:** Serum Life Science Europe GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-11-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01113281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01113281, "Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01113281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*